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Abstract
Backround:  Secondary hyperparathyroidism (SHPT) is a manifestation of  chronic kidney disease mineral bone disorder 
(CKD-MBD). SHPT is common in patients with chronic kidney disease (CKD) and is associated with significant morbidity and 
mortality.
Methods: A cross- sectional descriptive study involving 230 patients with CKD. 
Results: The mean age of  the study population was 44.17±15.24 years. The median intact parathyroid hormone and alkaline 
phosphatase levels were 96pg/ml (range 4-953pg/ml) and  88 iu/l (range 10-800 iu/l) respectively. The mean (with standard devi-
ation) calcium, serum phosphate, calcium phosphate product and haemoglobin levels were 2.22±0.29mmol/l, 1.8±0.62mmol/l, 
3.94±1.42mmol2/l2 and 9.90±1.87g/dl respectively. Majority of  patients had advanced CKD with 70.3% of  patients in stage 
G5. The prevalence rates of  SHPT, hypocalcaemia, hyperphosphataemia, elevated alkaline phosphatase and elevated calcium 
phosphate product were 55.2%, 34.8%, 66.1%, 42.2% and 25.2% respectively.
Univariate analysis revealed that SHPT was associated with hypocalcaemia, hyperphosphataemia, elevated alkaline phosphatase, 
proteinuria, anaemia, hypertension, left ventricular hypertrophy and stage of  kidney disease; being worse with advancing kidney 
disease. Independently associated with SHPT were hypocalcaemia (OR=4.84), hyperphosphataemia (OR=3.06), and elevated 
alkaline phosphatase (OR=2.04).
Conclusion: The prevalence of  SHPT in CKD is high, occurs early and is independently associated with hypocalcaemia, hy-
perphosphataemia and elevated alkaline phosphatase. The prevalence of  SHPT also increases with worsening renal function.
Keywords: Secondary hyperparathyroidism, chronic kidney disease, intact parathyroid hormone, hypocalcaemia, hyperphospha-
taemia, elevated alkaline phosphatase.
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Introduction
Chronic kidney disease (CKD) affects between 5 to 10% 
of  the population worldwide and is associated with signif-
icant morbidity and mortality mainly from cardiovascular 
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causes1-3.  A number of  endocrine and metabolic disor-
ders complicate CKD, one of  which is secondary hyper-
parathyroidism (SHPT). SHPT, a component of  Chronic 
Kidney Disease-Mineral and Bone Disorder (CKD-MBD) 
is defined by the presence of  elevated parathyroid hor-
mone (PTH) level as well as abnormalities in mineral and 
bone metabolism1,4-6. There is increasing prevalence of  
SHPT across declining glomerular filtration rates (GFR), 
and this has been identified as a risk factor for morbidity 
and mortality as it promotes vascular calcification among 
others7-9. The effects of  SHPT are manifested in different 
parts of  the body, causing bone pains, athralgia, muscle 
weakness, pruritus, bony deformities and increased frac-
ture risk4. The bone marrow fibrosis that can occur con-
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tributes to anaemia and erythropoietin resistance9. Thus, 
elevated PTH is considered a uremic toxin10,11.
SHPT occurs in 28.9% of  CKD patients in the Philip-
pines, 45% in Iranian patients and 55% of  American pa-
tients12-14. There are only few studies concerning this con-
dition in Africa15-17. SHPT occurs in 17-28. 1% of  Libyan 
CKD patients16,17. Previous studies in Nigeria utilising a 
small sample found SHPT in 18.1% of  patients in South 
West Nigeria15.  Another study in South Eastern Nigeria 
using only radiological features of  renal osteodystrophy 
found a low prevalence of  3.3%18. There is therefore the 
need for a larger study evaluating the burden of  SHPT in 
patients with CKD.
In this study, we hypothesise that SHPT is rare among 
Nigerians with CKD. We describe the prevalence of  
SHPT and its clinical correlates in a cross-sectional study 
involving CKD patients presenting in a teaching hospital 
in North Central Nigeria.
Patients and methods
Study design
This was a hospital based cross- sectional descriptive 
study, conducted between August 2011 and September 
2012. It was carried out in the Nephrology and Hyper-
tension Clinic and medical wards of  the Jos University 
Teaching Hospital (JUTH).
Study population
Patients 18 years and above attending the Nephrology 
and Hypertension Clinic or who were admitted into the 
medical wards of  JUTH and confirmed to have CKD 
were recruited using convenience sampling technique. 
CKD patients already on treatment for SHPT as well as 
pregnant CKD patients were excluded from the study.
Data collection
Demographic and clinical data were entered into a case 
report form. Information obtained included age, sex, 
weight, height, aetiology of  CKD, history of  body weak-
ness, pruritus, and bone tenderness. Height and Weight 
were measured in metres and kilograms using a stadiom-
eter and weighing scale with patients in light clothing, 
without head gears and without shoes. Body mass index 
(BMI) was calculated using the Quetelet index19.  Blood 
pressures were measured according to standard proce-
dures20.
Blood samples were obtained from the forearm vein 
of  each subject for intact parathyroid hormone (iPTH), 
haemoglobin, serum creatinine, albumin, calcium, phos-
phate, alkaline phosphatase. In addition, a 12 lead elec-
trocardiograph tracing, abdominal ultrasonography for 
renal sizes, as well as spot urine protein creatinine ratio 
determination was performed on all patients. Estimated 
glomerular filtration rate (eGFR) was calculated for each 
patient using the chronic kidney disease-epidemiology 
collaboration (CKD-EPI) formula21.
Laboratory methods
Enzyme linked immunosorbent assay (ELISA) kits (Di-
agnostic Automation Inc, California, USA)  were used for 
the determination of  biologically active  intact 84 amino 
acid chain of  PTH. In this reaction, iPTH binds to a poly-
clonal antibody that has been labelled with an indicator 
and binds only to the biologically active 84 amino chain 
of  PTH. The colour change by the indicator is propor-
tional to the concentration of  iPTH with absorbance 
read at 405nM. Concentrations of  iPTH are obtained 
using a dose response curve of  absorbance unit versus 
concentration.
Biochemical analysis for the determination of  serum 
calcium, phosphate, alkaline phosphatase, albumin, and 
serum lipids were all determined using an autoanalyser 
(Roche Diagnostics GmbH, Mannheim Germany).
In this study secondary hyperparathyroidism was de-
fined as iPTH≥65pg/ml, hyperphosphataemia was de-
fined as serum phosphate above 1.4mmol/l, hypocalcae-
mia was defined as corrected serum calcium level below 
2.1mmol/l, elevated calcium and phosphate product 
(CaXP) was defined as values greater than 4.5mmol2/l2 
while elevated alkaline phosphatase was serum total al-
kaline phosphatase above 96 iu/ml. Proteinuria was de-
fined as the presence trace amounts of  proteins in urine 
and above on conventional urinalysis strip (equivalent to 
15mg/dl and above).  Left ventricular hypertrophy was 
defined based on the Sokolow-Lyon criteria22.  
  
Ethical consideration
The human research and ethics committee of  the Jos 
University Teaching Hospital (JUTH) approved the study. 
All patients gave informed consent before recruitment. 
Data was anonymised by removing all patient identifiers. 
Data was kept safe until analysis.
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Statistical analysis
Epi - Info version 3.5.4 (CDC Atlanta USA) software was 
used for data analysis. Continuous variables with normal 
distribution were expressed as means ± SD while vari-
ables not normally distributed were expressed as medi-
an with ranges. Categorical variables were expressed as 
frequencies and percentages. Chi-square test was used to 
determine significance of  association between categorical 
variables. Fisher exact test was used when there were less 
than 5 observations. Student’s t- test was used to compare 
means. Multivariate analysis was used to identify variables 
independently associated with hyperparathyroidism. In 
this case, variables with a p value of  <0.25 on univariate 
analysis were entered into a multiple logistic regression 
model to determine their independent association with 
secondary hyperparathyroidism with backward elimina-
tion done to adjust for confounders. The use of  p <0.25 
is based on documented findings that the use of  p<0.05 
often fails to identify all variables known to be import-
ant23.  Level of  significance at p < 0.05 was used through-
out.
Results
A total of  230 CKD patients were enrolled for the study, 
one hundred and twenty six of  these patients (54.8%) 
were males while one hundred and four patients (45.2%) 
were females with a male to female ratio of  1.2:1. The 
mean age of  the study population was 44± 15 years. All 
patients were Black. Majority of  these patients (33.5%) 
had hypertension as the primary cause of  renal disease, 
followed by 30.9% with chronic glomerulonephritis and 
17% with diabetes mellitus (Figure 1). 
In addition, majority of  the patients had advanced renal 
disease with 70.3% of  them in CKD G5 and 16.1% in 
CKD G4 (Figure 2).  The socio-demographic and clinical 
characteristics of  the patients are as shown in Tables 1 
and 2 respectively.
CGN-Chronic Glomrulonephritis, HTN- Hypertension, DM- Diabetes Mellitus, SCD- Sickle cell disease,
 Obs- Obtructive uropathy, ADPKD- Autosomal dominant polycystic kidney disease, LN- Lupus nephritis
Figure 1: Bar graph showing aetiology of  CKD in the study population
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Figure 2: Bar graph showing CKD stages based on GFR categories
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Table 1: Socio demographic data of the study population 
Variable              Total (n=230 )          Females  (n=104)            Males (n=126)        p value 
Age,years             44.17 ±15.60             41.04±15.24                     46.73±15.45             0.005 
  
Weight (kg)          65.8±12.8                  63.7±14.0                         67.5±11.5                 0.003 
  
Height (M)           1.63±0.07                  1.59±0.05                         1.67±0.06               <0.0001 
  
BMI                      24.44±4.23                24.93 ±4.86                     24.02±3.58                0.27 
(Kg/M2) 
  
Education (n, %)                                                                                                               0.01 
   Uneducated          33 (14.4)                  22(21.2)                          11  (8.7)                     
   Primary                51 (22.2)                  27 (26.0)                         24 (19.0) 
   Secondary            66 (28.7)                  27 (26.0)                         39 (31.0) 
   Tertiary  and        80 (34.8)                  28 (27.0)                         42 (41.2) 
    above 
  
Marital status (n, %)                                                                                                    <0.0001 
   Married              152 (66.1)                  56 (53.8)                         96 (76.2)                                   
   Single                 51 (22.2)                    25 (24.0)                        26 (20.6) 
   Divorced            6 (2.6)                        5 (4.8)                            1 (0.8) 
   Widowed           21 (9.1)                      18 (17.3)                         3 (2.4) 
  
Occupation (n, %)                                                                                                         <0.0001 
   Employed            122 (53.0)                38 (36.5)                         84 (66.7)      
   Unemployed        79(34.4)                   48 (46.15)                       31 (24.60) 
   Student                 29 (12.6)                  18 (17.3)                        11 (8.7) 
  
Residence (n, %) 
   Rural                    56 (24.3)                  26 (25.0)                         30 (23.8)                    0.41   
   Urban                   174 (75.7)                78 (75.0)                         96 (76.2)  
  
  
Employed = civil servant, private employment, self employment), BMI= Body Mass Index. Values are 
in means±Standard Deviation or numbers (%), p values <0.05 are significant 
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Table 2: Biochemical parameters of the study population 
Variable                    Total (n=230)           Females (n=104)                  Males (n=126)             P value 
Proteinuria                 186 (80.9)                 86 (82.7)                              100 (79.4)                     0.52 
   (n,%) 
  
UPCR (mg/mg)         0.8 0.02-39.0              0.9 0.03-5.90                     0.70.02-39.00                 0.95 
median with range 
  
Creatinine (µmol/l) 564.50316.0-1000.0     623.50324.0-1000.0         539.0 308.0-981.0           0.45 
median with IQR 
  
eGFR((ml/min/1.73m2) 9.45.5-18.0             7.6 4.7-15.2                     10.9 6.5-21.7                   0.0003 
median with IQR 
  
Haemoglobin                 9.90±1.87               9.82±1.87                        9.97±1.87                         0.54 
    (g/dl) 
  
Serum albumin              35.95±7.76             35.45±6.83                      36.36±8.45                       0.77 
  (g/dl) 
  
Calcium corr.                 2.22±0.29              2.21±0.25                         2.24±0.33                         0.51 
   (mmol/l) 
  
Serum phosphate            1.8±0.62               1.81±0.83                         1.83±0.83                         0.64 
   (mmol/l) 
  
CaXP                               3.94±1.42            3.97±1.33                         3.91±1.49                         0.75 
  (mmol2/l2) 
  
Serum ALP  (iu/l)            8810-800            8510-221                           9025-800                         0.27 
  
Serum iPTH (pg/ml)       964-953               96 4-953                            94 4-953                          0.35 
  
Total cholesterol            4.81±1.61             5.06±1.49                          4.60±1.82                         0.004 
   (mmol/l) 
  
HDL (mmol/l)               1.06±0.50             1.08±0.58                          1.04±0.42                          0.71 
  
LDL (mmol/l)                2.81±1.34             2.98±1.27                          2.67±1.38                          0.08 
  
ECG (n,%)                                                                                                                                      0.51* 
Normal                          112 (49.3)             46 (45.1)                            66 (52.8)                       
LVH                              109 (52.0)             53 (52.0)                            56 (44.8)        
Low voltages                 6 (2.6)                   3 (2.9)                                3 (2.4)                    
Kidney sizes (cm) 
Right                             9.67±2.10              9.40±2.02                           9.90±2.15                         0.07 
Left                               9.76±2.32               9.35±2.09                          10.09±2.46                       0.01          
UPCR- Urine Protein Creatinine Ratio, eGFR- estimated Glomerular Filtration Rate, Calcium corr.-corrected calcium, CaXP- Calcium 
Phosphate product, ALP- Alkaline phosphatase, iPTH-intact parathyroid hormone, HDL-high density lipoprotein, LDL- low density 
lipoprotein, ECG- 
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Table 3 shows the prevalence of  SHPT, hypocalcaemia, 
hyperphosphataemia, elevated alkaline phosphatase, ele-
vated calcium phosphate product as well as anaemia in 
the study population. All of  these were compared be-
tween male and female patients. The prevalence of  SHPT 
was 55.2% overall with no significant difference between 
males and females (p = 0.70). 
Figure 3 is a bar graph showing the prevalence of  SHPT 
across CKD stages, with SHPT occurring as early as in 
CKD G3a and is highest in CKD G5. Additionally, with 
worsening of  the eGFR, the higher the mean values of  
phosphate, alkaline phosphatase, PTH and CaXP while 
lower mean values of  calcium were observed with wors-
ening of  eGFR (Figure 4).
Figure 3: Bar graph showing prevalence of  SHPT across different CKD stages
Table 3: Prevalence of shpt and other markers of CKD-MBD 
Variable                        Total (n=230)      Females (n=104)         Males (n= 126)       p value                                
 SHPT                           127(55.2)             56(53.8)                        71 (56.3)                0.70                  
(n,%) 
  
Hypocalcaemia               80 (34.8)             36(34.6)                        44 (34.9)                0.96 
(n,%) 
  
Hyperphosphataemia     152 (66.1)            74 (71.2)                       78 (61.9)                0.14 
(n,%) 
  
Elevated ALP                  97 (42.2)            39 (37.5)                       58 (46.0)               0.19     
(n,%) 
  
Elevated CaXP                58 (25.2)            29 (27.9)                        29 (23.0)               0.39                   
(n,%) 
  
Anaemia                        187 (81.3)            84 (80.8)                     103 (81.7)                0.85 
(n,%) 
SHPT- secondary hyperparathyroidism, ALP- alkaline phosphatase, CaXP- calcium phosphate product 
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The various factors associated with SHPT on univariate 
analysis are as shown in Table 4. SHPT was found to be 
associated with hypertension, proteinuria, low estimated 
glomerular filtration rate, left ventricular hypertrophy, 
hypocalcaemia, hyperphosphataemia, elevated alkaline 
phosphatase, elevated calcium phosphate product and 
anaemia. SHPT was not found to be associated with its 
clinical features as well as the aetiology of  the CKD. How-
ever on multivariate analysis, only hyperphosphataemia, 
hypocalcaemia and elevated alkaline phosphatase levels 
were found to be independently associated with SHPT 
and are shown in Table 5.
Figure 4 : Mean values of  calcium, phosphate, CaXP, iPTH and alkaline phosphatase 
levels across GFR ranges
African Health Sciences Vol 18 Issue 2, June, 2018 453
Table 4: univariate analysis of factors associated with SHPT 
VARIABLE SHPT NO SHPT            p value 
Age (mean ± SD) 
Sex 
  Females (n, %) 
  Males (n, %) 
Body weakness (n, %) 
Body pains (n, %) 
Pruritus (n, %) 
Bone tenderness (n, %) 
Scratch marks (n, %) 
Recent fracture (n, %) 
Hypertension (n, %) 
Proteinuria (n, %) 
eGFR mean(range) 
Elevated Cholesterol (n, %) 
Low HDL (n, %) 
Elevated LDL (n, %) 
Elevated Triglycerides (n, %) 
LVH on ECG (n, %) 
Hypocalcaemia (n, %) 
Hyperphosphataemia (n, %) 
Elevated ALP (n, %) 
Elevated CaXP (n, %) 
Anaemia (n, %) 
Diabetic nephropathy (n, %) 
 Hypertension (n, %) 
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14 (13.6)             
21 (20.4)             
41 (39.8)            
13 
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Table 5: factors independently associated with SHPT 
Variable (Yes/No)            Odds ratio                95% Confidence interval                 p value 
Hypocalcaemia                 5.41                             2.66-10.99                                    <0.0001 
  
Hyperphosphataemia        2.87                             1.52-5.41                                        0.001 
  
Elevated ALP                   2.04                             1.13-3.86                                        0.01               
 
Discussion
The prevalence of  SHPT among patients with CKD in 
Jos was found to be high and occurred in 55.2% of  sub-
jects studied. This study also found high prevalence rates 
of  hyperphosphataemia, hypocalcaemia, elevated alkaline 
phosphatase and anaemia. This is similar to that of  Bhan 
et al14 who reported a prevalence of  55% among CKD 
patients in the United States of  America. The prevalence 
of  SHPT found in this study is higher than earlier smaller 
studies by Sanusi et al15 and Odenigbo and colleagues18, 
thus showing that SHPT is common among Nigerians 
CKD patients than previously thought. The role of  the 
Black race in the development of  SHPT could also ex-
plain this high prevalence.  Studies by Gupta et al24 and 
Kalantar- Zadeh et al25 revealed that Black CKD patients 
have a 4.4 fold chance of  developing SHPT than White 
CKD patients. It is therefore not surprising that a large 
proportion of  the patients in this study have SHPT.
SHPT was also found to occur early with decreasing GFR 
levels and CKD categories. These findings are similar to 
those reported by Levin and colleagues7 in the SEEK 
study where SHPT occurred in up to 12% of  CKD pa-
tients with GFR above 80ml/min/1.73m2. This is per-
haps drawing attention to the fact that SHPT could pos-
sibly develop much earlier than GFR less than 60 ml/
min/1.73m2 and thus should be sought for in CKD pa-
tients at an early stage.
This study found no association between parathyroid 
hormone levels on the one hand and clinical features of  
SHPT on the other. This could be because symptoms 
and signs of  SHPT although common are non specific. 
In this study, the most common symptoms reported by 
the patients were body weakness, pruritus and bone pains 
with the least common feature being history of  fractures; 
a similar picture was described by Seck et al26 in Senegal 
who found that pruritus and bone pains were the most 
common symptoms and fractures the least. This however 
differed from the findings by Sanusi et al15 where majori-
ty of  their patients with CKD-MBD were asymptomatic. 
Clinical and biologic manifestations of  secondary hyper-
parathyroidism are non-specific and accurate diagnosis is 
difficult in the absence of  more specific diagnostic tests 
as is often the case in most resource poor settings like 
Nigeria.
The prevalence of  hypocalcaemia, hyperphosphatae-
mia, elevated alkaline phosphatase and elevated calcium 
phosphate product were all high in this study. These were 
all significantly associated with secondary hyperpara-
thyroidism on univariate analysis. All of  them, with the 
exception of  elevated calcium phosphate product were 
independently associated with secondary hyperparathy-
roidism. This concurs with the finding of  Sanusi et al15 
where high prevalence of  hypocalcaemia, hyperphos-
phataemia as well as increased alkaline phosphatase were 
seen in their patients with renal bone disease, which in 
a number of  studies has been linked to increased mor-
tality in patients with secondary hyperparathyroidism. 
Hypocalcaemia, hyperphosphataemia, elevated alkaline 
phosphatase and elevated calcium and phosphate prod-
uct (CaXP) were also found to have higher prevalence 
rates with decreasing glomerular filtration rates. Thus the 
more severe the kidney damage, the higher the prevalence 
of  these markers, a finding similar to that of  Levin et al.7
To our knowledge, this the largest study on SHPT in Ni-
geria, which has shown that SHPT is common among 
our CKD patients. This study also found no association 
between SHPT and its clinical features, thus stressing the 
need for the provision of  facilities for the detection of  
SHPT, which often is not the case in resource limited set-
tings like ours. Our study was limited by the inability to 
detect skeletal and extra skeletal manifestations of  SHPT 
as well as novel biomarkers like FGF-23.
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Conclusion
SHPT is common in CKD patients in Jos, Nigeria and 
is independently associated with hypocalcaemia, hyper-
phosphataemia and elevated alkaline phosphatase levels. 
It increases with worsening renal function and occurs as 
early as CKD stage G3a. SHPT is not associated with its 
clinical features, thus it is important that facilities for the 
determination of  iPTH be made available for the early 
detection and management of  SHPT.
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